Syal Simran, Rao Sudha, Joshi Rajesh, Keshwani Rachna, Bodhanwala Minnie
Department of Pediatrics, Division of Pediatric Endocrinology, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India.
Indian J Endocrinol Metab. 2023 May-Jun;27(3):230-236. doi: 10.4103/ijem.ijem_248_22. Epub 2023 Jun 26.
Primary dyslipidaemia in children is a rare inherited disorder of lipoprotein metabolism with debilitating sequelae and poor outcomes. Lipid-lowering drugs have less often been used in children and long-term outcome studies are scarce. The purpose of this study was to understand the clinical and laboratory profile, response to treatment on follow up and outcome of primary dyslipidaemia in Indian children.
Clinical records, including historical details, examination features and laboratory and radiological evaluation of children diagnosed with primary dyslipidaemia, presenting over the last 9 years were studied. Cascade screening was done for family members of the patients to detect dyslipidaemia in parents and siblings. All children were followed up 3 to 6 monthly for clinical and laboratory evaluation. Diet and drug therapy, initiated as appropriate, were modified as necessary.
Of nine children with primary dyslipidaemia, seen over the last 9 years, homozygous familial hypercholesterolaemia (HoFH) (n = 4/9), familial hypertriglyceridaemia (FHT) (n = 3/9), familial combined hyperlipidemia (FCH) (n = 1/9), mutation proven chylomicronaemia syndrome (n = 1/9) were the phenotypes seen. Multiple xanthomas (n = 4/9), recurrent pancreatitis (n = 2/9) and incidentally found biochemical abnormality (n = 3/9) were the chief presenting features. Medical nutrition therapy and lipid-lowering drugs, as appropriate, were instituted in all. Follow-up over 16 months (range 4 to 90 months) revealed no deaths and no new onset of symptoms. Atherosclerotic plaques in the carotid artery were seen in one child, who presented late, despite fair compliance to treatment. Interestingly, lipid levels decreased in all cases and were normalised in two.
Primary dyslipidaemia when detected early and treated aggressively can improve short-term outcomes.
儿童原发性血脂异常是一种罕见的脂蛋白代谢遗传性疾病,会导致严重后果且预后不佳。降脂药物在儿童中较少使用,长期预后研究也很匮乏。本研究的目的是了解印度儿童原发性血脂异常的临床和实验室特征、随访时的治疗反应及预后。
对过去9年中诊断为原发性血脂异常的儿童的临床记录进行研究,包括病史细节、检查特征以及实验室和影像学评估。对患者家属进行级联筛查,以检测父母和兄弟姐妹中的血脂异常情况。所有儿童每3至6个月进行一次随访,以进行临床和实验室评估。根据需要启动饮食和药物治疗,并进行必要的调整。
在过去9年中见到的9例原发性血脂异常儿童中,观察到的表型有纯合子家族性高胆固醇血症(HoFH)(n = 4/9)、家族性高甘油三酯血症(FHT)(n = 3/9)、家族性混合型高脂血症(FCH)(n = 1/9)、经突变证实的乳糜微粒血症综合征(n = 1/9)。主要表现特征为多发性黄色瘤(n = 4/9)、复发性胰腺炎(n = 2/9)和偶然发现的生化异常(n = 3/9)。所有患者均酌情采用了医学营养治疗和降脂药物。16个月(范围4至90个月)的随访显示无死亡病例,也无新症状出现。一名就诊较晚的儿童尽管对治疗依从性尚可,但颈动脉出现了动脉粥样硬化斑块。有趣的是,所有病例的血脂水平均下降,其中两例恢复正常。
原发性血脂异常早期发现并积极治疗可改善短期预后。